JAK2 and anemia (phenotype): For instance, although upadacitinib is a JAK1-selective inhibitor, the incidence of anemia, one of the adverse effects of JAK2 inhibition, was higher in patients treated with 30 mg of upadacitinib than in those treated with 15 mg of upadacitinib or placebo during 16 weeks (166).